ASX Announcement, Chimeric Therapeutics to Undertake Entitlement Offer

Key Highlights

• Entitlement Offer to raise up to $3.2 million at $0.005 per share on a 2-for-5 basis.
• 1 new option (exercise price $0.008, expiry 19 December 2025) per 1 new share subscribed (subject to shareholder approval).
• Funds to support CHM CDH17 Phase 1/2 clinical trial and ongoing research.
• Eligible shareholders can participate at the offer price with potential for additional shares.

Entitlement Offer Details

Chimeric Therapeutics (ASX: CHM) has announced its intention to undertake a pro-rata non-renounceable Entitlement Offer to raise approximately $3.2 million before costs. The offer price is $0.005 per share, representing:

• 23.1% discount to the last closing price of $0.0065 (26 February 2025).
• 28.6% discount to the 5-day VWAP of $0.007.

Additional Benefit: Shareholders subscribing to the offer will receive 1 free option per new share (exercise price $0.008, expiry 19 December 2025), subject to shareholder approval.

New shares issued under the Entitlement Offer will rank equally with existing shares. Eligible shareholders who do not take up their entitlement will not receive any value for their unclaimed entitlements.

Upon distribution of the offer documentation, shareholders will also have the opportunity to apply for additional shares over their pro-rata entitlement. Further details are expected to be released by 18 March 2025.

Use of Funds

Proceeds from the offer will support:

• CHM CDH17 CAR-T Program: Ongoing Phase 1/2 clinical trials for neuroendocrine tumors, colorectal cancer, and gastric cancer.
• CORE NK Platform: Phase 1B clinical trials in colorectal and blood cancers, in partnership with Case Western University and MD Anderson Cancer Center.
• CHM CLTX CAR-T Program: Phase 1B clinical trials for glioblastoma multiforme (GBM – Brain Cancer), with promising early results.
• General working capital and capital raising costs.

PAC Partners and Taylor Collison have been appointed as lead managers for the Entitlement Offer.

CEO Statement

Chimeric CEO Dr. Rebecca McQualter commented:
“Following our recent $4 million non-dilutionary funding and early success in our CHM CDH17 clinical trial, we are excited to continue development efforts. This Entitlement Offer provides an opportunity for our shareholders to actively participate and support Chimeric at this pivotal stage.”

About Chimeric Therapeutics

Chimeric Therapeutics is an Australian leader in clinical-stage cell therapy, dedicated to developing and commercializing innovative cell therapies for cancer treatment. Its portfolio includes autologous CAR-T cell therapies and allogeneic NK cell therapies, currently undergoing clinical trials across multiple oncology areas.

• CHM CDH17 CAR-T: A first-in-class therapy from the University of Pennsylvania, targeting gastrointestinal and neuroendocrine tumors.
• CHM CLTX CAR-T: Designed for solid tumors, currently in a Phase 1B trial for recurrent glioblastoma.
• CHM CORE-NK: A clinically validated NK cell platform, with two Phase 1B trials exploring its effectiveness in combination therapies.

Chimeric continues to drive cutting-edge research and clinical advancements in cell therapy.